- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06255275
Impact of Perceptive, Executive and Emotional Factors on Decision-making of Pedestrian Face to Autonomous Vehicles. (VASIS)
November 22, 2024 updated by: Centre Hospitalier Universitaire de Besancon
Impact of Perceptive, Executive and Emotional Factors on Decision-making in the Context of Pedestrian Crossing in an Industrial Environment Involving Traffic of Autonomous Vehicles (forklifts)
The VASIS project aims to assess the impact of perceptual, executive and emotional factors on decision-making in the context of pedestrian crossing in an industrial environment involving autonomous vehicle traffic (forklift).
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
100
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Besançon, France
- Besançon University Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- subjects aged 18 to 45
- no objection following submission of a non-objection form indicating that the subject has understood the purpose and procedures of the study and agrees to participate in the study and to comply with the requirements and restrictions inherent in the study
Exclusion Criteria:
- legal incapacity or limited legal capacity
- subject unlikely to cooperate with the study and/or poor cooperation anticipated by the investigator
- pregnant or breast-feeding women
- color-blind subject
- history of cardiovascular disease
- current psychiatric or neurological disorders (including self-reported diagnoses of epilepsy)
- known vestibular disorders (prone to frequent dizziness or vertigo)
- headaches or migraines
- deafness
- subjects under the influence of psychotropic substances (alcohol, drugs)
- motor disorders likely to prevent crossing
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: pedestrian crossing - virtual reality
|
Neurocognitive tests (attention, executive functions, reaction to difficulty).
Assessment of anxiety and impulsivity + pedestrian crossign with virtual reality + post-crossing questionnaire
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Evaluation of the impact of the attention of participants on decision-making in the context of pedestrian crossing (virtual reality), particularly on the time required to cross safely, in an industrial environment involving autonomous vehicle traffic.
Time Frame: Day 0
|
Quantication of the time required for a pedestrian to cross safely, according to the attention of participants
|
Day 0
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
April 8, 2024
Primary Completion (Actual)
July 8, 2024
Study Completion (Actual)
July 8, 2024
Study Registration Dates
First Submitted
February 5, 2024
First Submitted That Met QC Criteria
February 5, 2024
First Posted (Actual)
February 13, 2024
Study Record Updates
Last Update Posted (Estimated)
November 26, 2024
Last Update Submitted That Met QC Criteria
November 22, 2024
Last Verified
April 1, 2024
More Information
Terms related to this study
Other Study ID Numbers
- 2023/787
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Decision-making
-
Massachusetts General HospitalUnknownDecision Making | Video Decision AidsUnited States
-
Brigham and Women's HospitalCompleted
-
University of ZurichPfizerCompletedDecision MakingSwitzerland
-
University Hospital, Clermont-FerrandCompleted
-
Umraniye Education and Research HospitalCompleted
-
University of UtahNational Institutes of Health (NIH)Completed
-
Rush University Medical CenterNot yet recruiting
-
Rutgers, The State University of New JerseyNational Institute on Drug Abuse (NIDA)Recruiting
-
Boston CollegeCompleted
-
Instituto Tecnologico y de Estudios Superiores...Completed
Clinical Trials on neurocognitifs tests + pedestrian crossign whith virtual reality
-
Centre Hospitalier Universitaire de NīmesCompleted
-
Queen's University, BelfastUniversity of SussexUnknownRetinitis Pigmentosa | Low Vision | Albinism | Stargardt Disease 1 | Stargardt Disease 3 | Stargardt Disease 4United Kingdom
-
Charite University, Berlin, GermanyFreie Universität Berlin; NeuroCure Clinical Research Center, Charite, Berlin; Humboldt-Universität zu Berlin and other collaboratorsCompleted
-
Assistance Publique - Hôpitaux de ParisURC-CIC Paris Descartes Necker CochinRecruitingVestibular DiseasesFrance
-
University Hospital, CaenCompletedRelapsing-Remitting Multiple SclerosisFrance
-
University Hospital, BordeauxCompletedCognitive Impairment | Sleep Disorders | Sleep ArchitectureFrance
-
Imperial College LondonRecruitingHearing Loss | Aminoglycoside Toxicity | Video Games | Aminoglycoside-Induced Hearing LossUnited Kingdom